We are live on ! Find out more
LLY icon

Eli Lilly

1,561 hedge funds and large institutions have $94.2B invested in Eli Lilly in 2018 Q4 according to their latest regulatory filings, with 229 funds opening new positions, 453 increasing their positions, 596 reducing their positions, and 86 closing their positions.

New
Increased
Maintained
Reduced
Closed

166% more first-time investments, than exits

New positions opened: 229 | Existing positions closed: 86

72% more funds holding in top 10

Funds holding in top 10: 3662 (+26)

9% more funds holding

Funds holding: 1,4321,561 (+129)

6% more capital invested

Capital invested by funds: $88.7B → $94.2B (+$5.5B)

0.95% more ownership

Funds ownership: 77.08%78.03% (+0.95%)

7% less call options, than puts

Call options by funds: $739M | Put options by funds: $797M

24% less repeat investments, than reductions

Existing positions increased: 453 | Existing positions reduced: 596

Holders
1,561
Holders Change
+129
Holders Change %
+9.01%
% of All Funds
34.77%
Holding in Top 10
62
Holding in Top 10 Change
+26
Holding in Top 10 Change %
+72.22%
% of All Funds
1.38%
New
229
Increased
453
Reduced
596
Closed
86
Calls
$739M
Puts
$797M
Net Calls
-$58.2M
Net Calls Change
+$119M
Name Holding Trade Value Shares
Change
Change in
Stake
BTS
226
BB&T Securities
Virginia
$18.4M +$235K +2,101 +1%
Impax Asset Management Group
227
Impax Asset Management Group
United Kingdom
$18.4M -$2.98M -26,721 -14%
WBC
228
Westpac Banking Corp
Australia
$18.3M +$1.67M +14,949 +10%
Mariner
229
Mariner
Kansas
$17.7M +$7.72M +69,096 +82%
ZIG
230
Zurich Insurance Group
Switzerland
$17.7M -$2.18M -19,540 -11%
Cambridge Investment Research Advisors
231
Cambridge Investment Research Advisors
Iowa
$17.7M -$285K -2,549 -2%
PIA
232
Piedmont Investment Advisors
North Carolina
$17.6M -$1.25M -11,176 -7%
GC
233
Guggenheim Capital
Illinois
$17.4M -$2.51M -22,489 -13%
BAMF
234
BI Asset Management Fondsmaeglerselskab
Denmark
$17.1M -$3.31M -29,600 -17%
CS
235
Candriam SCA
Luxembourg
$17.1M -$1.61M -14,379 -9%
QI
236
QS Investors
New York
$17M +$5.66M +50,642 +52%
GF
237
Gabelli Funds
New York
$17M -$4.64M -41,500 -22%
HA
238
H2O AM
United Kingdom
$16.9M +$18.3M +163,432 New
ProShare Advisors
239
ProShare Advisors
Maryland
$16.8M +$521K +4,662 +3%
JCM
240
Jag Capital Management
Missouri
$16.7M +$1.13M +10,105 +8%
WorldQuant Millennium Advisors
241
WorldQuant Millennium Advisors
New York
$16.6M +$3.83M +34,258 +31%
KeyBank National Association
242
KeyBank National Association
Ohio
$16.6M -$375K -3,356 -2%
NMIMC
243
Northwestern Mutual Investment Management Company
Wisconsin
$16.5M -$2.76M -24,671 -15%
CAM
244
ClariVest Asset Management
California
$16.5M +$15.9M +142,499 New
ECM
245
Element Capital Management
New York
$16.3M +$15.7M +140,684 New
ANI
246
American National Insurance
Texas
$16.3M
SB
247
Suntrust Banks
Georgia
$16.3M -$3.01M -26,932 -16%
TAF
248
Tredje AP-fonden
Sweden
$16.2M -$6.12M -54,752 -28%
SGI
249
Summit Global Investments
Utah
$16M +$834K +7,463 +6%
NONA
250
Ninety One North America
New York
$15.7M -$6.81M -60,999 -31%

LLY Hedge Fund Activity: Q4 2018 in Review

1,561 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Eli Lilly (LLY) for Q4 2018, worth a combined $94.2B — up 6.2% from $88.7B a quarter earlier.

Buyers outnumbered sellers: 229 funds opened new LLY positions and 86 closed out — a net gain of 143 holders — while 453 added to existing stakes and 596 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $1.59B. The largest seller was Franklin Resources, cutting an estimated $1.17B.

  • 1,561 institutional investors held Eli Lilly (LLY) as of Q4 2018, up from 1,432 in Q3 2018.
  • Funds reported $94.2B of Eli Lilly stock for Q4 2018, up 6.2% quarter-over-quarter.
  • 229 funds opened new Eli Lilly positions in Q4 2018 and 86 closed out, a net change of +143 holders.
  • The largest Eli Lilly buyer in Q4 2018 was T. Rowe Price Associates, an estimated $1.59B added.
  • The largest Eli Lilly seller in Q4 2018 was Franklin Resources, an estimated $1.17B sold.

Based on aggregated 13F filings for Q4 2018.